ISB President Dr. Jim Heath talked with Science in Seattle in a wide-ranging interview that touched on his paper in Cell Reports showing how T-cell receptors form, his transition from chemistry to biology, challenges facing life scientists, and more.
As AI and new imaging tools give researchers vast amounts of data on tumors, they are winning some battles against cancer. ISB President Dr. Jim Heath was interviewed for this extensively reported feature story for Newsweek Magazine.
ISB Associate Professor Dr. Sean Gibbons spoke with Mark O. Martin from the University of Puget Sound. Gibbons talked about how the study of host-associated microbial communities gives us insights into evolution, ecology and human health.
ISB and NED Biosystems will collaborate on an intriguing clinical trial that aims to use a cocktail of several marketed medications at low doses to reverse cancer’s onset or regrowth. ISB Co-founder Lee Hood and NED Biosystems founder and CEO Rebecca Lambert announced the deal.
Sean Gibbons was quoted in this Bloomberg Businessweek story examining Viome and the often questionable microbiome-wellness startup space.
This story published by Inside Precision Medicine covers ISB research showing that the different disease-fighting functions of distinct T cells are determined by the genetically encoded T-cell receptor (TCR) sequence that are unique to those cells. The findings are promising for developing custom immune responses to specific antigens.
McKnights Senior Living published a news story detailing results from the ISB-led Coaching for Cognition in Alzheimer’s (COCOA) trial showing that supplementing the standard of care for early-stage Alzheimer’s disease with lifestyle coaching leads to less cognitive decline.
ISB researchers collaborated on an international research project that found a way to determine which species in the gut are important and how they interact to create a healthy microbiome.
ISB Associate Professor Dr. Sean Gibbons was a guest on the ISAPP Science, Microbes & Health podcast. In this episode, Gibbons talked about exploring and manipulating the complex ecology of the microbiome with the aim of engineering outputs of this system, as well as the utility of AI in microbiome science and how the microbiome will play a role in personalized medicine in the future, including in the delivery of probiotics and prebiotics.
The Journalist’s Resource featured work by ISB researchers showing four predictive factors of long COVID. The Journalist’s Resource was created by Harvard Kennedy School’s Shorenstein Center on Media, Politics and Public Policy as an open-access online publication for journalists.
The ISB-led prospective randomized controlled trial called COCOA – Coaching for Cognition in Alzheimer’s – showed that supplementing personalized coaching along with the standard of treatment leads to less cognitive decline in early-stage Alzheimer’s patients than standard of care alone.
The Economist highlights work by several ISB researchers showing that gut microbiome patterns reflect healthy aging and predict survival in humans. The work was originally published in the scientific journal Nature Metabolism.
Lee Hood and Nathan Price were guests on the Doctor’s Farmacy podcast, and spoke with Dr. Mark Hyman about the future of personalized healthcare through scientific wellness, how AI is changing the medical industry, and much more.
Lee Hood and Nathan Price discuss their approach to scientific wellness – distilling data into a simple, actionable measurement: biological age. Their goal is to leverage technology to compile data from the brain, body, gut microbiome, and more to create a model for scientific wellness.
Senior Research Scientist Cory Funk was interviewed for a story looking at viruses being the cause of Alzheimer’s disease and examining a preprint paper showing that a shingles vaccine could prevent 20 percent of dementia cases.
Dr. Lee Hood is featured in a CBC News story and video, and discusses using data to transform health, designing customized wellness plans based on individuals’ genetic risk profiles, and more.
Nathan Price was interviewed for the Modern Healthspan podcast, where he talked about scientific wellness, measuring wellness, the microbiome, and much more.
Sean Gibbons was a guest on The Gutology Podcast. In the roughly 45-minute conversation, Gibbons talked about his microbiome research, what worries him in the research field, what he’s excited about, and much more.
ISB researchers have identified a network within Mycobacterium tuberculosis, the pathogen that causes tuberculosis, that allows it to tolerate and resist drug therapies. When the network is disrupted, Mtb’s cells are unable to properly divide, compromising their cell wall – a key defense mechanism.
This news story details an ISB-led study showing that maternal-fetal outcomes are improved when pregnant women receive COVID-19 vaccines and boosters.